Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XANTHOS: Sacituzumab tirumotecan in previously treated unresectable thymic carcinoma
jRCT2031260381Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2027
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in thymic carcinoma (TC), sponsored by Merck & Co. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on jRCT2031260381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260381.